Latest Headlines
Stereotactic radiation controls early stage lung cancer
Melanoma survivors at higher risk of other cancers
Cladribine and fludarabine equally helpful for progressive CLL
More frequent surveillance reduces colon cancer risk in Lynch syndrome families
Radiation can be avoided in early Hodgkin's lymphoma
NEWS PROVIDED BY 
VIEW ALL NEWSImatinib suppresses breast cancer bone metastases by inhibiting osteoclasts
NEW YORK (Reuters Health) - Imatinib mesylate suppresses bone metastases from breast cancer by blocking signals from the macrophage colony-stimulating factor (M-CSF) receptor c-Fms and thereby inhibiting osteoclasts, according to a report in the January 1st International Journal of Cancer.
"In addition to the direct anti-cancer effects, imatinib also has an inhibitory effect on osteoclasts, the key player in the development of bone metastases," Dr. Toru Hiraga told Reuters Health.
Dr. Hiraga and Dr. Hiraoki Nakamura from Matsumoto Dental University, Shiojiri, Nagano, Japan, investigated the effects of imatinib on bone metastases of breast cancer with a special focus on osteoclasts.
Imatinib attenuated the phosphorylation of c-Fms induced by M-CSF in mouse osteoclasts, the authors report, and dose dependently inhibited osteoclast-like cell formation induced by M-CSF and receptor activator of nuclear factor kappa-beta ligand (RANKL).
Imatinib also induced apoptosis in osteoclast precursors, but not at the low doses used to inhibit osteoclast differentiation.
Moreover, the researchers note, the lower concentrations of imatinib used to suppress osteoclast differentiation did not affect osteoblast differentiation.
In nude mice bearing bone metastases, imatinib significantly decreased the number and area of osteolytic lesions, as well as the metastatic tumor burden and osteoclast number in bone metastases, the investigators say, and these effects were reproduced by specific inhibition of c-Fms.
"The inhibitory effects of imatinib against osteoclastic bone resorption may provide a beneficial effect on cancer-induced bone loss, one of the frequent complications caused by hormonal therapy and chemotherapy," Dr. Hiraga concluded.
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 